DMTweet: a psychedelic tweet recap

a PsyMed Ventures x Business Trip colab (issue #3)

DMTweet is a newsletter of psychedelic tweets that catch our eye 👀.

This is a collaboration between PsyMed Ventures and Business Trip (yes, we’re the folks working on both 🙃).

Tweets include: Industry updates 💼, Therapy 🛋️, Psychedelic research 🧪, Neuroscience 🧠, Consciousness ✨, Indigenous reciprocity ⚖️, Regulatory updates 📜, and Trippy ideas 👽.

Inclusion = interesting ≠ endorsement.

Let’s get to it….

Matthew W. Johnson @Drug_Researcher

Big news! We've published our 1-year follow-up of our trial of #psilocybin for depression. The massive decreases in depression were unshaken a year later. Mystical experience in the session was related to improved well-being a year later. Great thread by 1st author @N_Gukasyan

Natalie Gukasyan, MD @N_Gukasyan

Long-term (12 month follow-up) results of our waiting-list controlled study of psilocybin-assisted therapy for MDD are out today in JOP: https://t.co/pm0WV55CMl 1/ 🧵

Olson Lab @DEOlsonLab

nice paper from the de Wit group: "We conclude that within the context of a controlled setting and a limited number of administrations, repeated low doses of LSD are safe, but produce negligible changes in mood or cognition in healthy volunteers."

onlinelibrary.wiley.comRepeated low doses of LSD in healthy adults: A placebo‐controlled, dose–response studyMicrodosing of psychedelic drugs to enhance mood or cognition is a popular practice, but scientific evidence is lacking. In this study, healthy adults received repeated single low doses of LSD (13 or...

Andrew D. Huberman, Ph.D. @hubermanlab

Areas of science not long ago considered fringe that now have federal (& other) support & 100s of labs at top institutions working to define mechanism/uses: 1) Gut microbes (& Diet) 2) Psychedelics 3) Deliberate Breathing Makes you ask: what’s fringe now soon to be a focus?

Dr. Marina Harris, Ph.D. @DrMarinaHarris

What's the BEST mental health advice you've ever received?

Nikhil Krishnan @nikillinit

IMO mental health companies are overly fixated on distribution (e.g. going through employer channels) than changing the core of the problem - we don't have enough supply (clinicians) to meet demand or good ways to measure patient progress

Ethan Mollick @emollick

Shockingly, mindfulness apps really work. This randomized controlled trial on the Headspace app finds it reduces anxiety and depression by a huge .44 standard deviations after 4 weeks - in the same range as drug treatment & cognitive behavioral therapy. adviksh.com/files/in_progr…

Laci Green @gogreen18

I think we're going to see a lot more VR therapy in the future. A new study found 30% of people prefer to discuss negative experiences as an avatar. VR seems to offer a way to "log out" of our bodies for a moment & feel more safe. v cool possibilities

bigthink.comHow virtual reality will change how we see ourselves and therapyWe are capable of embodying a virtual environment surprisingly quickly. This has huge implications for therapy and interpersonal relations.

Yeji Jesse Lee 이예지 @jesse_yeji

A project months in the making: here's @BusinessInsider's inaugural list of the most influential women in the psychedelics space. @drcatherinesb and I sorted through hundreds of nominations to come up with the list you see below.

businessinsider.comMeet the 16 most influential women shaping the future of psychedelicsInsider pored through 158 names to come up with our inaugural list of The Most Influential Women in Psychedelics.

Until next time…

Greg, Matias, and Dina

🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄

🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄

DMTweet is a collab between PsyMed Ventures and Business Trip. PsyMed Ventures is a community-focused fund and syndicate investing in psychedelic medicine and mental health tech. Business Trip is a podcast about psychedelic entrepreneurship. Our mission is to help expand access to psychedelic medicine and mental health.